ASH 2021 | Phase I study of PLX51107, a novel BET inhibitor, in combination with azacitidine in R/R MDS and AML
Naveen Pemmaraju, MD, University of Texas MD Anderson Cancer Center, Houston, TX, outlines the results of a Phase I study examining the safety and preliminary efficacy of PLX51107, a bromodomain and extra-terminal domain (BET) inhibitor, in combination with azacitidine in patients with high-risk myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) (NCT04022785). This combination appeared to be well tolerated and showed some efficacy signals with signs of hematologic improvement (HI) in high-risk AML subsets. BET inhibition should be further investigated in combination with other agents in patients with myeloid malignancies. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
Disclosures
Naveen Pemmaraju, MD, is a member of the ASH Communications Committee and the ASCO Leukemia Advisory panel; has participated in consultancy work for Pacylex Pharmaceuticals, ImmuniGen, Bristol Myers Squibb, Blueprint Medicines, Clearview Healthcare Partners, Astellas Pharma US Inc., Triptych Health Partners and CTI Biopharma; has received grants from Affymetrix and SagerStrong Foundation; has received honoraria from Incyte, Novartis, LFB Biotechnologies, Stemline Therapeutics, Celgene, AbbVie, MustangBio, Roche Diagnostics, Blueprint Medicines, DAVA Oncology, Springer Science + Business Media LLC, Aptitude Health, NeoPharm Israel and CareDx, Inc., has received research support from Novartis, Stemline Therapeutics, Samus Therapeutics, AbbVie, Cellectis, Affymetrix, Daiichi Sankyo and Plexxikon; and has received travel reimbursement from Stemline Therapeutics, Celgene, MustangBio, DAVA Oncology and AbbVie.
